The convergence of artificial intelligence (AI) and healthcare is ushering in a new era of medical innovation. As AI models continue to evolve, their potential to revolutionize patient care becomes increasingly evident. Google's Med-Gemini, a family of AI models specifically tailored for medical applications, represents a significant leap forward in this...
As always, the chart is easy to read and understand. Here are a couple of highlights for this case study: Observed a strong breakout with a long candle, currently in a retest phase. Recent price action shows a clear buyer bias. Key support levels are holding at 892 and 864. The 21-weekly EMA provides additional support. Volume spiked significantly...
In a groundbreaking move that could redefine the landscape of obesity treatment, Eli Lilly has slashed the price of its weight loss drug, Zepbound, by half. But is this simply a strategic business decision, or is it a beacon of hope for millions struggling with obesity? Join us as we delve into the implications of this bold move and explore the potential impact on...
After a couple of tests the price has finally broken above the W Formation (Neckline and Downtrend). The price is above 20 and 200MA which makes it a high probability analysis... It looks great for upside to R16.53. 'I'm bullish
If the stock drops a few points, I'll be buying very heavily... CVS and WBA are in the same sector. And both have been decimated. CVS, however, is doing better. And they're paying a dividend. Target, at least +10%. Trading at 70% below estimate of its fair value Earnings are forecast to grow 9% per year Earnings grew by 140% over the past year DIVIDEND = Pays a...
Trading at 75.8% below our estimate of its fair value Earnings are forecast to grow 83.28% per year Trading at good value compared to peers and industry WBA stock is a strong buy due to its consistent dividend yield, robust global presence, and strategic initiatives in healthcare and retail. The company's expansion into digital health positions it for future growth.
As a managed health care company, Centene Corp NYSE:CNC doesn't get much attention. However, it is an undervalued growth stock. It's been a workhorse historically for slow and steady financial returns with a 3%+ dividend. The biggest dips along my selected moving average have been into the blue lines - which it recently tested. While the stock may close the gap...
Rev Cup and Handle formed on Netcare, we then had a MAJOR swoosh up in one day. This broke not only above the 20MA and 200MA but also above the January downtrend. So the movement is looking very positive for the healthcare stock. Target R14.73
GE Healthcare aka GEHC is a renowned global medical technology, pharmaceutical diagnostics, and digital solutions company that aims to revolutionize healthcare by eliminating limits. With a diverse portfolio of innovative products, services, and solutions, GEHC empowers healthcare professionals to make informed decisions quickly and improve patient care across the...
Life Health Care was presenting a simple Head and Shoulders with a usual drop for a short. The price started off well then went to the entry. Wake up and not only did it go past R15.96 target... The market opened aty R10.80 exceeding our expectations and profits. It's these trades that we absolutely love and can't help but get excited when things go...
Buy $4 dollar stock. Sell $7 or $12. place Stop loss 0.50c below the dashed-line for your protection. Live-Laugh-Love. Let's make 2024 great.
AMEX:PILL On the 4H Chart, current market price is sitting on the support of order blocks and the EMA200, while in an uptend from a double bottom in the sprint. It is moving into the high volume area of the voluxme profile. For the swing trade, the stop loss is $0.10 below the EMA200 while the targets are marked based on a combination of the horizontal...
Achyut Healthcare Ltd is a pharmaceutical trading company that was established in 1996 and is based in Ahmedabad, Gujarat. The company trades in pharmaceutical products, medical devices, and APIs. It manufactures tablets, capsules, oral liquids, and injectables, and also customizes products for domestic and international markets. looking for 59 price in upcoming...
AMEX:XLV has formed a five-week equilibrium. The price contraction is already quite tight, indicating that this equilibrium could break very soon. The context is highly bullish: the XLV price is on a weekly uptrend, and the broader market is also showing strong performance. The odds are in favor of an upside breakout. On the chart, there is an example of a...
Last time we looked into United Health (UNH) we gave a strong buy signal (October 03 2023, see chart below), which turned out to be very successful: After getting rejected on Resistance 3, the stock started to decline structurally within a Channel Down. It is a pattern similar to the Channel Down of November 2022 - March 2023, which was again formed after UNH...
Positive news on phase 3 trials. Possible US food & drug admin application next year 2025 8.5 times the usual 20 daily volume average. Red to green reversal. This all points towards likely higher prices. If their application next year gets approved expect a monster move. Investors will likely try to front run this.
Eli Lilly (LLY) has basically turned sideways since the February 16 High. The dominant pattern is a Channel Up since the March 07 2023 Low and can be divided into 3 Bullish Waves that delivered rallies between +45% and +52%. Every time the price hit the 1D MA50 (blue trend-line), it was a buy opportunity. The 1D RSI in particular has a Buy Zone, which coincided...
Dr Lal Pathlabs one of the largest players of healthcare industry in India has a beaten down stock price currently. It is approximately 53.29% down from it's lifetime high. There is not a single reason for such stock price. The company is posting good results and is consistently showing profits. But the stock is highly undervalued. It is a good time to buy it as...